Liu et al. applied multi-omics integration and machine-learning classification to stratify HER2 + /ER+ breast cancers, illustrating the power of computational approaches for dissecting clinically relevant HER2-associated tumor heterogeneity [49]. This evidence concerns the gene ERBB2 and breast cancer.